A novel antibody–drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity-Reference-Cited by-同舟云学术

A novel antibody–drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity

Published:2015-07-23 Issue:1 Volume:24 Page:47-57
ISSN:1061-186X
Container-title:Journal of Drug Targeting
language:en
Short-container-title:Journal of Drug Targeting

Author:

Jiang Linlin¹,Yang Ming¹,Zhang Xiaoyun¹,Bao Shiqi¹,Ma Li¹,Fan Dongmei¹,Zhou Yuan¹,Xiong Dongsheng¹,Zhen Yongsu²

Affiliation:

1. State key Laboratory of Experimental Hematology, Institute of Hematology and Hospital of Blood Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, China and

2. Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, China

Publisher

Informa UK Limited

Subject

Pharmaceutical Science

Link

https://www.tandfonline.com/doi/pdf/10.3109/1061186X.2015.1055568

Reference40 articles.

1. Cancer statistics, 2012

2. Non-Hodgkin’s Lymphomas

3. Ten years of rituximab in NHL

4. Diversity in antibody-based approaches to non-Hodgkin lymphoma

5. Rituximab resistance

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antitumor efficacy of a recombinant EGFR-targeted fusion protein conjugate that induces telomere shortening and telomerase downregulation;International Journal of Biological Macromolecules;2023-01

2. Development of Traceable Rituximab-Modified PEO-Polyester Micelles by Postinsertion of PEG-phospholipids for Targeting of B-cell Lymphoma;ACS Omega;2019-11-01

3. An Engineered Fusion Protein Anti-CD19(Fab)-LDM Effectively Inhibits ADR-Resistant B Cell Lymphoma;Frontiers in Oncology;2019-09-04